Advancing Epigenetic Therapies to Treat Liver Diseases with James Brown DVM DURECT

Published: Feb. 19, 2020, 4:28 p.m.

James Brown DVM, CEO, DURECT Corporation talks about how DURECT is advancing epigenetic therapies to treat alcoholic hepatitis and non-alcoholic steatohepatitis (NASH).\xa0 The company's lead asset, DUR-928 has demonstrated promising therapeutic potential treating patients with alcoholic hepatitis, a life-threatening acute liver disease caused by chronic alcohol abuse with no approved drugs for treatment.\xa0 Dr. Brown also talks about his background as a doctor of veterinary medicine and his goal to continue developing medicines that improve the lives of others.

#AlcoholicHepatits #Epigenetic #NASH #LiverDisease

DURECT.com

Download the transcript here